{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T03:40:17Z","timestamp":1792381217109,"version":"4.4.0"},"update-to":[{"DOI":"10.1002\/14651858.cd015738","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000}}],"reference-count":106,"publisher":"Wiley","issue":"8","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd015738.pub2","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T12:07:53Z","timestamp":1786450073000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["First-line systemic treatment for people with extensive-stage small cell lung cancer: a network meta-analysis"],"prefix":"10.1002","volume":"2026","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4731-6032","authenticated-orcid":false,"given":"Takenori","family":"Ichimura","sequence":"additional","affiliation":[{"name":"Drug Informatics Group, Laboratory of Clinical Pharmacy, School of Pharmacy; Tokyo University of Pharmacy and Life Sciences; Tokyo Japan"},{"name":"Institute of Clinical Epidemiology; Showa Medical University; Tokyo Japan"},{"name":"Department of Hospital Pharmaceutics, School of Pharmacy; Showa Medical University; Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Sugita","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmaceutics, School of Pharmacy; Showa Medical University; Tokyo Japan"},{"name":"Institute of Clinical Epidemiology; Showa Medical University; Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Noma","sequence":"additional","affiliation":[{"name":"Department of Interdisciplinary Statistical Mathematics; The Institute of Statistical Mathematics; Tokyo Japan"},{"name":"Institute of Clinical Epidemiology; Showa Medical University; Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noyuri","family":"Yamaji","sequence":"additional","affiliation":[{"name":"Institute of Clinical Epidemiology; Showa Medical University; Tokyo Japan"},{"name":"Department of Family Nursing, Division of Health Sciences and Nursing, Graduate School of Medicine; The University of Tokyo; Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomiko","family":"Sunaga","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology, Division of Applied Pharmaceutical Education and Research; Hoshi University; Tokyo Japan"},{"name":"Institute of Clinical Epidemiology; Showa Medical University; Tokyo Japan"},{"name":"Department of Hospital Pharmaceutics, School of Pharmacy; Showa Medical University; Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki Takenaka","family":"Sato","sequence":"additional","affiliation":[{"name":"Division of Pharmacotherapeutics, Department of Clinical Pharmacy, School of Pharmacy; Showa Medical University; Tokyo Japan"},{"name":"Institute of Clinical Epidemiology; Showa Medical University; Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Maeda","sequence":"additional","affiliation":[{"name":"Division of Infection Control Sciences, Department of Clinical Pharmacy, School of Pharmacy; Showa Medical University; Tokyo Japan"},{"name":"Institute of Clinical Epidemiology; Showa Medical University; Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Toyoda","sequence":"additional","affiliation":[{"name":"Torrance Memorial Medical Center; California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Ota","sequence":"additional","affiliation":[{"name":"Global Health Nursing; St. Luke\u2019s International University; Tokyo Japan"},{"name":"Institute of Clinical Epidemiology; Showa Medical University; Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Institute of Clinical Epidemiology; Showa Medical University; Tokyo Japan"},{"name":"Department of Nephrology, Graduate School of Medicine; Showa Medical University; Tokyo Japan"},{"name":"Department of Hygiene, Public Health, and Preventive Medicine, Graduate School of Medicine; Showa Medical University; Tokyo Japan"},{"name":"Center for Innovative Research for Communities and Clinical Excellence; Fukushima Medical University; Fukushima Japan"},{"name":"Department of Healthcare Epidemiology, School of Public Health in the Graduate School of Medicine; Kyoto University; Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"issue":"3","key":"10.1002\/14651858.CD015738.pub2-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"209\u201349","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"1243\u201360","DOI":"10.1097\/JTO.0000000000000630","article-title":"The 2015 World Health Organization Classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification","volume":"10","author":"Travis","year":"2015","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"362\u201387","DOI":"10.1016\/j.jtho.2021.11.003","article-title":"The 2021 WHO classification of lung tumors: impact of advances since 2015","volume":"17","author":"Nicholson","year":"2022","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"4539\u201344","DOI":"10.1200\/JCO.2005.04.4859","article-title":"Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database","volume":"24","author":"Govindan","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"143\u201356","DOI":"10.1016\/j.hoc.2016.08.005","article-title":"Advances in small cell lung cancer","volume":"31","author":"Kalemkerian","year":"2017","journal-title":"Hematology, Oncology Clinics of North America"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"271\u20136","DOI":"10.1016\/s0169-5002(02)00072-7","article-title":"Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer \u2212 what limits limited disease?","volume":"37","author":"Micke","year":"2002","journal-title":"Lung Cancer"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"300\u201311","DOI":"10.1016\/j.jtho.2015.10.008","article-title":"The International Association for the Study of Lung Cancer staging project: proposals for the revision of the clinical and pathologic staging of small cell lung cancer in the forthcoming eighth edition of the TNM Classification for Lung Cancer","volume":"11","author":"Nicholson","year":"2016","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"1471\u20134","DOI":"10.1245\/s10434-010-0985-4","article-title":"The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM","volume":"17","author":"Stephen","year":"2010","journal-title":"Annals of Surgical Oncology"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"842\u20137","DOI":"10.1016\/j.neo.2017.07.007","article-title":"What's new in SCLC? A review","volume":"19","author":"Oronsky","year":"2017","journal-title":"Neoplasia"},{"issue":"6","key":"10.1002\/14651858.CD015738.pub2-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"e35770","DOI":"10.1002\/cncr.35770","article-title":"Top advances of the year: Small cell lung cancer","volume":"131","author":"Shields","year":"2025","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"78\u201398","DOI":"10.6004\/jnccn.2013.0011","article-title":"Small cell lung cancer","volume":"11","author":"Kalemkerian","year":"2013","journal-title":"Journal of the National Comprehensive Cancer Network"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"1741\u201355","DOI":"10.1016\/S0140-6736(11)60165-7","article-title":"Small-cell lung cancer","volume":"378","author":"Van Meerbeeck","year":"2011","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"629\u201338","DOI":"10.1097\/COC.0000000000000867","article-title":"Treatment and prevention of brain metastases in small cell lung cancer","volume":"44","author":"Rittberg","year":"2021","journal-title":"American Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"445\u201354","DOI":"10.1007\/s11136-020-02615-1","article-title":"The impact of symptoms and comorbidity on health utility scores and health-related quality of life in small cell lung cancer using real world data","volume":"30","author":"Vedadi","year":"2021","journal-title":"Quality of Life Research"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0015|cit15","doi-asserted-by":"publisher","first-page":"671\u201380","DOI":"10.1200\/JCO.21.01881","article-title":"Extensive-stage small-cell lung cancer: first-line and second-line treatment options","volume":"40","author":"Zugazagoitia","year":"2022","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"535\u201354","DOI":"10.1016\/S0140-6736(21)00312-3","article-title":"Lung cancer","volume":"398","author":"Thai","year":"2021","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0017|cit17","doi-asserted-by":"publisher","first-page":"3536\u201346","DOI":"10.1111\/1759-7714.13698","article-title":"Efficacy and safety of PD-1\/PD-L1 inhibitor plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small cell lung cancer: a systematic review and meta-analysis","volume":"11","author":"Zhang","year":"2020","journal-title":"Thoracic Cancer"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0018|cit18","doi-asserted-by":"publisher","first-page":"1929\u201339","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"2220\u20139","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD015738.pub2-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"844\u201361","DOI":"10.1016\/j.apsb.2018.07.008","article-title":"Recent developments in topoisomerase-targeted cancer chemotherapy","volume":"8","author":"Hevener","year":"2018","journal-title":"Acta Pharmaceutica Sinica B"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0021|cit21","doi-asserted-by":"publisher","first-page":"364\u201378","DOI":"10.1016\/j.ejphar.2014.07.025","article-title":"Cisplatin in cancer therapy: molecular mechanisms of action","volume":"740","author":"Dasari","year":"2014","journal-title":"European Journal of Pharmacology"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"2831\u20137","DOI":"10.1158\/1078-0432.CCR-13-3141","article-title":"Molecular pathways: the immunogenic effects of platinum-based chemotherapeutics","volume":"20","author":"Hato","year":"2014","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3389\/fphar.2017.00561","article-title":"PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome","volume":"8","author":"Alsaab","year":"2017","journal-title":"Frontiers in Pharmacology"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0024|cit24","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s11912-020-00970-3","article-title":"Immune oncology biomarkers in lung cancer: an overview","volume":"22","author":"Travert","year":"2020","journal-title":"Current Oncology Reports"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"747180","DOI":"10.3389\/fphar.2021.747180","article-title":"Absence of biomarker-driven treatment options in small cell lung cancer, and selected preclinical candidates for next generation combination therapies","volume":"12","author":"Liguori","year":"2021","journal-title":"Frontiers in Pharmacology"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"228\u201347","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0027|cit27","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) v5.0 ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0028|cit28","doi-asserted-by":"publisher","first-page":"7412\u201320","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0029|cit29","unstructured":"Higgins JPT Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions. Version 6.5 (updated August 2024). Cochrane, 2024 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0030|cit30","doi-asserted-by":"publisher","first-page":"777\u201384","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0031|cit31","doi-asserted-by":"publisher","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLOS Medicine"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0032|cit32","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2026"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0033|cit33","unstructured":"Dias S Welton NJ Sutton AJ Ades AE NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials (last updated September 2016) Available from www.nicedsu.org.uk 2011"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0034|cit34","doi-asserted-by":"publisher","first-page":"312\u201324","DOI":"10.1002\/jrsm.1058","article-title":"Network meta-analysis, electrical networks and graph theory","volume":"3","author":"R\u00fccker","year":"2012","journal-title":"Research Synthesis Methods"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0035|cit35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v106.i02","article-title":"netmeta: An R package for network meta-analysis using frequentist methods","volume":"106","author":"Balduzzi","year":"2023","journal-title":"Journal of Statistical Software"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"2815\u201334","DOI":"10.1002\/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0038|cit38","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12874-022-01541-9","article-title":"Implications of analysing time-to-event outcomes as binary in meta-analysis: empirical evidence from the Cochrane Database of Systematic Reviews","volume":"22","author":"Salika","year":"2022","journal-title":"BMC Medical Research Methodology"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"629\u201334","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0040|cit40","unstructured":"Confidence in Network Meta-Analysis Papakonstantinou T Nikolakopoulou A Salanti G Institute of Social and Preventive Medicine 2017"},{"issue":"1","key":"10.1002\/14651858.CD015738.pub2-BIB0041|cit41","doi-asserted-by":"publisher","first-page":"e1080","DOI":"10.1002\/cl2.1080","article-title":"CINeMA: Software for semiautomated assessment of the confidence in the results of network meta-analysis","volume":"16","author":"Papakonstantinou","year":"2020","journal-title":"Campbell Systematic Reviews"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0042|cit42","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1186\/s12916-021-02166-3","article-title":"ROB-MEN: a tool to assess risk of bias due to missing evidence in network meta-analysis","volume":"19","author":"Chiocchia","year":"2021","journal-title":"BMC Medicine"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0043|cit43","unstructured":"netmeta: Network Meta-Analysis using Frequentist Methods R\u00fccker G Schwarzer G Krahn U K\u00f6nig J The R Foundation for Statistical Computing 2025"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0044|cit44","doi-asserted-by":"publisher","first-page":"l6890","DOI":"10.1136\/bmj.l6890","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline","volume":"368","author":"Campbell","year":"2020","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0045|cit45","unstructured":"NMA: Network Meta-Analysis Package for R Noma H Maruo K Tanaka S Furukawa TA The R Foundation for Statistical Computing 2023"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0046|cit46","doi-asserted-by":"crossref","unstructured":"survNMA: Network Meta-Analysis Combining Survival and Count Outcomes Noma H The R Foundation for Statistical Computing 2025","DOI":"10.32614\/CRAN.package.survNMA"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0047|cit47","doi-asserted-by":"publisher","first-page":"163\u201371","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0048|cit48","doi-asserted-by":"publisher","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in STATA","volume":"8","author":"Chaimani","year":"2013","journal-title":"PLOS One"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0049|cit49","doi-asserted-by":"publisher","first-page":"1539\u201358","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0050|cit50","doi-asserted-by":"publisher","first-page":"98\u2013110","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies","volume":"3","author":"Higgins","year":"2012","journal-title":"Research Synthesis Methods"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0051|cit51","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime)"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0052|cit52","doi-asserted-by":"publisher","first-page":"36\u201344","DOI":"10.1016\/j.jclinepi.2017.10.005","article-title":"Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis","volume":"93","author":"Brignardello-Petersen","year":"2018","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0053|cit53","doi-asserted-by":"publisher","first-page":"60\u20137","DOI":"10.1016\/j.jclinepi.2018.08.022","article-title":"GRADE approach to rate the certainty from a network meta-analysis: avoiding spurious judgments of imprecision in sparse networks","volume":"105","author":"Brignardello-Petersen","year":"2019","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0054|cit54","doi-asserted-by":"publisher","first-page":"77\u201385","DOI":"10.1016\/j.jclinepi.2018.11.025","article-title":"GRADE approach to rate the certainty from a network meta-analysis: addressing incoherence","volume":"108","author":"Brignardello-Petersen","year":"2019","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0055|cit55","doi-asserted-by":"publisher","first-page":"g5630","DOI":"10.1136\/bmj.g5630","article-title":"A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis","volume":"349","author":"Puhan","year":"2014","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD015738.pub2-BIB0056|cit56","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41392-024-02115-5","article-title":"A multicenter, randomized, double-blind, placebo-controlled phase 3 study of socazolimab or placebo combined with carboplatin and etoposide in the first-line treatment of extensive-stage small cell lung cancer","volume":"10","author":"Chen","year":"2025","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"12","key":"10.1002\/14651858.CD015738.pub2-BIB0057|cit57","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1001\/jama.2022.16464","article-title":"Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: the ASTRUM-005 randomized clinical trial","volume":"328","author":"Cheng","year":"2022","journal-title":"JAMA"},{"issue":"10","key":"10.1002\/14651858.CD015738.pub2-BIB0058|cit58","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1038\/s41591-024-03132-1","article-title":"Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial","volume":"30","author":"Cheng","year":"2024","journal-title":"Nature Medicine"},{"issue":"7","key":"10.1002\/14651858.CD015738.pub2-BIB0059|cit59","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.jtho.2024.03.008","article-title":"Tislelizumab plus platinum and etoposide versus placebo plus platinum and etoposide as first-line treatment for extensive-stage SCLC (RATIONALE-312): a multicenter, double-blind, placebo-controlled, randomized, phase 3 clinical trial","volume":"19","author":"Cheng","year":"2024","journal-title":"Journal of Thoracic Oncology"},{"issue":"1","key":"10.1002\/14651858.CD015738.pub2-BIB0060|cit60","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1001\/jamaoncol.2024.5019","article-title":"Toripalimab plus chemotherapy as a first-line therapy for extensive-stage small cell lung cancer: the phase 3 EXTENTORCH randomized clinical trial","volume":"11","author":"Cheng","year":"2025","journal-title":"JAMA Oncology"},{"issue":"23","key":"10.1002\/14651858.CD015738.pub2-BIB0061|cit61","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD015738.pub2-BIB0062|cit62","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1200\/JCO.20.01055","article-title":"Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133)","volume":"39","author":"Liu","year":"2021","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD015738.pub2-BIB0063|cit63","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.annonc.2019.10.021","article-title":"Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I\/III trial","volume":"31","author":"Mansfield","year":"2020","journal-title":"Annals of Oncology"},{"issue":"12","key":"10.1002\/14651858.CD015738.pub2-BIB0064|cit64","doi-asserted-by":"publisher","first-page":"e35938","DOI":"10.1002\/cncr.35938","article-title":"Randomized phase II clinical trial of cisplatin\/carboplatin and etoposide (PE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161","volume":"131","author":"Leal","year":"2025","journal-title":"Cancer"},{"issue":"10212","key":"10.1002\/14651858.CD015738.pub2-BIB0065|cit65","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD015738.pub2-BIB0066|cit66","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1158\/1078-0432.CCR-23-1689","article-title":"Durvalumab \u00b1 tremelimumab + platinum-etoposide in extensive-stage small cell lung cancer (CASPIAN): outcomes by PD-L1 expression and tissue tumor mutational burden","volume":"30","author":"Paz-Ares","year":"2024","journal-title":"Clinical Cancer Research"},{"issue":"2","key":"10.1002\/14651858.CD015738.pub2-BIB0067|cit67","doi-asserted-by":"publisher","first-page":"100408","DOI":"10.1016\/j.esmoop.2022.100408","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN","volume":"7","author":"Paz-Ares","year":"2022","journal-title":"ESMO Open"},{"issue":"1","key":"10.1002\/14651858.CD015738.pub2-BIB0068|cit68","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S1470-2045(20)30539-8","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial","volume":"22","author":"Goldman","year":"2021","journal-title":"Lancet Oncology"},{"issue":"31","key":"10.1002\/14651858.CD015738.pub2-BIB0069|cit69","doi-asserted-by":"publisher","first-page":"3740","DOI":"10.1200\/JCO.2016.67.6601","article-title":"Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer","volume":"34","author":"Reck","year":"2016","journal-title":"Journal of Clinical Oncology"},{"issue":"21","key":"10.1002\/14651858.CD015738.pub2-BIB0070|cit70","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1200\/JCO.20.00793","article-title":"Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 Study","volume":"38","author":"Rudin","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD015738.pub2-BIB0071|cit71","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1200\/JCO.23.01363","article-title":"SKYSCRAPER-02: Tiragolumab in combination with atezolizumab plus chemotherapy in untreated extensive-stage small-cell lung cancer","volume":"42","author":"Rudin","year":"2024","journal-title":"Journal of Clinical Oncology"},{"issue":"28","key":"10.1002\/14651858.CD015738.pub2-BIB0072|cit72","doi-asserted-by":"publisher","first-page":"4787","DOI":"10.1200\/JCO.2009.23.1548","article-title":"Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer","volume":"27","author":"Socinski","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"10.1002\/14651858.CD015738.pub2-BIB0073|cit73","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1200\/JCO.2016.69.4844","article-title":"Italian, multicenter, phase III, randomized study of cisplatin plus etoposide with or without bevacizumab as first-line treatment in extensive-disease small-cell lung cancer: the GOIRC-AIFA FARM6PMFJM trial","volume":"35","author":"Tiseo","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD015738.pub2-BIB0074|cit74","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S1470-2045(22)00224-8","article-title":"Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Wang","year":"2022","journal-title":"Lancet Oncology"},{"issue":"1","key":"10.1002\/14651858.CD015738.pub2-BIB0075|cit75","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S1470-2045(20)30539-8","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial","volume":"22","author":"Goldman","year":"2021","journal-title":"Lancet Oncology"},{"issue":"2","key":"10.1002\/14651858.CD015738.pub2-BIB0076|cit76","doi-asserted-by":"publisher","first-page":"100408","DOI":"10.1016\/j.esmoop.2022.100408","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN","volume":"7","author":"Paz-Ares","year":"2022","journal-title":"ESMO Open"},{"issue":"6","key":"10.1002\/14651858.CD015738.pub2-BIB0077|cit77","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1200\/JCO.20.01055","article-title":"Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133)","volume":"39","author":"Liu","year":"2021","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD015738.pub2-BIB0078|cit78","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1158\/1078-0432.CCR-23-1689","article-title":"Durvalumab \u00b1 tremelimumab + platinum-etoposide in extensive-stage small cell lung cancer (CASPIAN): outcomes by PD-L1 expression and tissue tumor mutational burden","volume":"30","author":"Paz-Ares","year":"2024","journal-title":"Clinical Cancer Research"},{"issue":"2","key":"10.1002\/14651858.CD015738.pub2-BIB0079|cit79","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.annonc.2019.10.021","article-title":"Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I\/III trial","volume":"31","author":"Mansfield","year":"2020","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0080|cit80","doi-asserted-by":"publisher","first-page":"S19\u201324","DOI":"10.21037\/tlcr.2017.12.12","article-title":"PACIFIC trial: new perspectives for immunotherapy in lung cancer","volume":"7","author":"Agustoni","year":"2018","journal-title":"Transl Lung Cancer Res"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0081|cit81","doi-asserted-by":"crossref","unstructured":"Charlot M Gray JE First-line Immunotherapy and Clinically Meaningful Survival Benefits for the Oldest Adults With Lung Cancer JAMA Oncol 2023 9 3 342 3 10.1001\/jamaoncol.2022.6867","DOI":"10.1001\/jamaoncol.2022.6867"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0082|cit82","doi-asserted-by":"crossref","unstructured":"El Kaddissi A Basse C New European approvals: Durvalumab - In first line metastatic small-cell lung cancer Bull Cancer 2020 107 12 1208 9 10.1016\/j.bulcan.2020.10.003","DOI":"10.1016\/j.bulcan.2020.10.003"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0083|cit83","doi-asserted-by":"crossref","unstructured":"Kartolo A Robinson A Fung AS Optimal first-line immune checkpoint inhibitor treatment in lung cancer: how to choose? Future Oncol 2022 18 6 635 638 10.2217\/fon-2021-1348","DOI":"10.2217\/fon-2021-1348"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0084|cit84","doi-asserted-by":"crossref","unstructured":"Kim C Subramaniam DS Liu SV Giaccone G Phase I\/II trial of anti-PD-1 checkpoint inhibitor nivolumab and Lu-DOTA-Tyr-Octreotate for patients with extensive-stage small cell lung cancer Journal of Clinical Oncology ASCO Annual Meeting 2018 TPS8589","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS8589"},{"issue":"10","key":"10.1002\/14651858.CD015738.pub2-BIB0085|cit85","doi-asserted-by":"publisher","first-page":"1556\u20138","DOI":"10.1016\/j.jtho.2020.08.013","article-title":"Another Brick in the Wall: sintilimab Plus Chemotherapy in Advanced Lung Cancer","volume":"15","author":"Lam","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"23","key":"10.1002\/14651858.CD015738.pub2-BIB0086|cit86","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.1111\/1759-7714.14697","article-title":"Investigation of poor predictive factors in extensive stage small cell lung cancer under etoposide-platinum-atezolizumab treatment","volume":"13","author":"Lim","year":"2022","journal-title":"Thorac Cancer"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0087|cit87","doi-asserted-by":"crossref","unstructured":"First-Line Atezolizumab OK'd for SCLC Cancer Discov 2019 9 5 568 9 10.1158\/2159-8290.CD-NB2019-042","DOI":"10.1158\/2159-8290.CD-NB2019-042"},{"issue":"15","key":"10.1002\/14651858.CD015738.pub2-BIB0088|cit88","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1200\/JCO.23.00061","article-title":"Combination Immune Checkpoint Inhibition: Is First Line Best?","volume":"41","author":"McArthur","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0089|cit89","doi-asserted-by":"crossref","unstructured":"Miller RA Cagle PT Bernicker EH First-Line Immune Therapy-Implications for Pathologists Arch Pathol Lab Med 2016 140 8 739 40 10.5858\/arpa.2016-0904-ED","DOI":"10.5858\/arpa.2016-0904-ED"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0090|cit90","unstructured":"Final outcome, immunophenotypic and biomarker analysis of intercalated avelumab plus platinum-based chemotherapy in patients with extensive-stage small cell lung cancer (PAVE): A pilot phase II study of the Hellenic co-operative oncology group ESMO Open 2024"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0091|cit91","doi-asserted-by":"crossref","unstructured":"Mullard A Immuno-oncology drugs jostle for first-line setting Nat Rev Drug Discov 2016 15 11 738 10.1038\/nrd.2016.227","DOI":"10.1038\/nrd.2016.227"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0092|cit92","unstructured":"REACTION: A Phase II Study of Etoposide and Cis\/Carboplatin With or Without Pembrolizumab in Untreated Extensive Small Cell Lung Cancer https:\/\/clinicaltrials.gov\/study\/NCT02580994 2017"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0093|cit93","unstructured":"A Phase 3, Randomized, Double-Blind Study of Ociperlimab, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer https:\/\/clinicaltrials.gov\/study\/NCT04746924 2021"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0094|cit94","unstructured":"A Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Etoposide and Cisplatin or Carboplatin for the First-Line Treatment of Participants With Extensive-Stage Small Cell Lung Cancer (KEYNOTE-B99) https:\/\/clinicaltrials.gov\/study\/NCT04924101 2021"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0095|cit95","unstructured":"Durvalumab (MEDI4736) Combined With Anlotinib Versus Durvalumab (MEDI4736) Alone as Maintenance Therapy in Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) https:\/\/clinicaltrials.gov\/study\/NCT04985851 2021"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0096|cit96","unstructured":"Orlov S Levashev Y Bigday T Kozhemyakin L Smirnov A Combination immunotherapy and chemotherapy for advanced small-cell lung cancer not available 2000 16 Suppl 31 528s"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0097|cit97","doi-asserted-by":"crossref","unstructured":"Peng J Meng R Liu X Zhang L Wang L Feng R A Chinese multicenter, real-world study of PD-L1 inhibitors in extensive stage small cell lung cancer J Thorac Oncol 2023 S135 10.1016\/S1556-0864(23)00426-4","DOI":"10.1016\/S1556-0864(23)00426-4"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0098|cit98","doi-asserted-by":"crossref","unstructured":"Schafer A Chemoimmunotherapy as a standard for ED-SCLC - CASPIAN trial shows survival benefit with durvalumab after 3 years Oncol Res Treat 2023 46 338\u20139 10.1159\/000532047","DOI":"10.1159\/000532047"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0099|cit99","unstructured":"A Randomized, Open-label Study of Serplulimab Plus Chemotherapy (Carboplatin-Etoposide) in Comparison With Atezolizumab Plus Chemotherapy in Previously Untreated US Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) (ASTRIDE) https:\/\/clinicaltrials.gov\/study\/NCT05468489 2022"},{"issue":"8","key":"10.1002\/14651858.CD015738.pub2-BIB0100|cit100","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006849.pub3","article-title":"Platinum versus non-platinum chemotherapy regimens for small cell lung cancer","author":"Amarasena","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0101|cit101","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.lungcan.2023.02.003","article-title":"Efficacy and safety of first-line immune checkpoint inhibitors combined with chemotherapy for extensive-stage small cell lung cancer: A network meta-analysis","volume":"178","author":"Wang","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1002\/14651858.CD015738.pub2-BIB0102|cit102","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1111\/1759-7714.15310","article-title":"First-line treatments for extensive-stage small cell lung cancer with immune checkpoint inhibitors: a systematic review and network meta-analysis","volume":"15","author":"Yang","year":"2024","journal-title":"Thorac Cancer"},{"issue":"10495","key":"10.1002\/14651858.CD015738.pub2-BIB0103|cit103","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1016\/S0140-6736(25)01011-6","article-title":"Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial","volume":"405","author":"Paz-Ares","year":"2025","journal-title":"Lancet"},{"issue":"10","key":"10.1002\/14651858.CD015738.pub2-BIB0104|cit104","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/S1470-2045(25)00480-2","article-title":"Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study","volume":"26","author":"Paulson","year":"2025","journal-title":"Lancet Oncology"},{"issue":"4","key":"10.1002\/14651858.CD015738.pub2-BIB0105|cit105","doi-asserted-by":"publisher","first-page":"261\u201373","DOI":"10.1200\/JCO-25-02142","article-title":"Ifinatamab deruxtecan in patients with extensive-stage small cell lung cancer: primary analysis of the phase II IDeate-Lung01 trial","volume":"44","author":"Rudin","year":"2026","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD015738.pub2-BIB0106|cit106","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015738","article-title":"First-line systemic treatment for people with extensive-stage small cell lung cancer: a systematic review and network meta-analysis","author":"Ichimura","year":"2024","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T03:02:54Z","timestamp":1792378974000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD015738.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":106,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd015738.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]}}}